Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PGEN, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Zopapogene Imadenovec (PRGN-2012) | Recurrent Respiratory Papillomatosis | Phase 4 · NCT06538480 | Recruiting |
| Zopapogene imadenovec-drba | Recurrent Respiratory Papillomatosis (RRP) | Phase 3 · NCT07901738 | Not yet recruiting |
| AG019 - High Dose | Diabetes type1 | Phase 1/2 · NCT03751007 | Completed |
| Gorilla-derived Adenovirus-expressing HPV-16/18… | Cervical Cancer | Phase 2 · NCT06157151 | Recruiting |
| Fludarabine | Chronic Lymphocytic Leukemia | Phase 1 · NCT05694364 | Completed |
| INXN-4001 | Heart Failure | Phase 1 · NCT03409627 | Completed |
| Autologous Anti-MUC16 CAR-mbIL15-Safety Switch… | Platinum-Resistant Fallopian Tube Carcinoma | Phase 1 · NCT03907527 | Active not recruiting |
| Autologous Anti-CD33 CAR-mbIL15-Safety Switch… | Acute Myeloid Leukemia | Phase 1 · NCT03927261 | Active not recruiting |
| Autologous Anti-ROR1 CAR-mbIL15-Safety… | Chronic Lymphocytic Leukemia | Phase 1 · NCT05694364 | Completed |
Also used in these trials (approved or third-party drugs, not PGEN's own candidates): Teplizumab, Cyclophosphamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PGEN holds $51M in cash and short-term investments (as of Sep 30, 2026) and burns about $3M/quarter from operations, an estimated runway of 51.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PGEN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Randal J Kirk Director, 10% owner |
Insider | 133,956,416 | 37.36% | 2026-03-30 |
| Patient Capital Management, LLC | Institution (13G, 5%+) | 36,006,800 | 10.04% | 2025-12-31 |
| Helen Sabzevari President and CEO · +2.10M options |
Insider | 3,779,521 | 1.05% | 2026-08-23 |
| Steven Frank Director |
Insider | 1,226,391 | 0.34% | 2026-03-13 |
| Cesar L Alvarez Director |
Insider | 782,909 | 0.22% | 2026-03-13 |
| Donald P. Lehr Chief Legal Officer · +415,292 options |
Insider | 758,181 | 0.21% | 2026-08-23 |
| Vinita D Gupta Director |
Insider | 666,027 | 0.19% | 2026-03-13 |
| Rutul R Shah Chief Operating Officer · +525,596 options |
Insider | 468,865 | 0.13% | 2026-08-21 |
| Harry Jr. Thomasian Chief Financial Officer · +1.37M options |
Insider | 311,914 | 0.09% | 2026-09-23 |
| Nancy H Agee Director |
Insider | 309,187 | 0.09% | 2026-08-21 |
| Phil Tennant Chief Commercial Officer · +563,126 options |
Insider | 141,992 | 0.04% | 2026-08-23 |
| Jeffrey B Kindler Director |
Insider | 17,100 | 0.00% | 2026-08-26 |
Share count 358,549,980 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-08-27 | PAPZIMEOS | BLA | +169.6% | +7.8% | +11.5% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PGEN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →